Efficacy of Ifosfamide, Carboplatin and Etoposide Protocol in the Treatment of Relapsed or Refractory Bone and Soft Tissue Sarcomas
Musa Baris Aykan1, Gul Sema Yildiran1, Ece Akcan1, Ramazan Acar1, Ismail Erturk1, Nuri Karadusmus11Department of Medical Oncology, University of Health Sciences, Gulhane Faculty of Medicine, Ankara, Türkiye
Objectives: To aim to show the survival outcomes of ifosfamide, carboplatin and etoposide (ICE) therapy and the characteristics of treatment-related hematological side effects in patients with relapsed/refractory bone sarcomas (BSs) and soft tissue sarcomas (STSs). Methods: Patients who were treated at the Department of Medical Oncology, Gulhane School of Medicine between January 2017 and June 2021 were included. Post-ICE progression-free survival (PFS), overall survival (OS) rates and treatment-related hematological side effects were determined. Results: Fifty-six adult patients were included (thirty-four of them BSs). PFS was determined as 6.7 ± 4.4 months and 7.1±3.6 months for STSs and BSs, respectively. OS was 11.4±5.6 monhts and 12.6±7.1 for STSs and BSs, respectively. PFS and OS were not found to be better between groups (p=0.84 and p=0.517, respectively). The median OS and PFS after ICE protocol in patients with two or less systemic chemotherapy lines were significantly higher than those who received three or more lines (7.85±1.66 vs 3.74 ±2.89, p=0.001 and 13.80±8.45 vs 6.73, p=0.001). Conclusion: In addition to its contribution for all patients, ICE may contribute to longer survival, especially in patients receiving ?2 lines of systemic chemotherapy. Keywords: Bone sarcoma, carboplatin, etoposide, ifosfamide, soft tissue sarcoma
Cite This Article
Aykan M, Yildiran G, Akcan E, Acar R, Erturk I, Karadusmus N. Efficacy of Ifosfamide, Carboplatin and Etoposide Protocol in the Treatment of Relapsed or Refractory Bone and Soft Tissue Sarcomas. EJMI. 2022; 6(3): 299-303
Corresponding Author: Musa Baris Aykan